Application Area: Lung Disease

Technologies 4

• AAV-Engineering For Advanced Gene Therapy
  Gene therapy with AAV (adeno-associated virus) as a delivery vehicle is a leading therapeutic modality for genetic disorders that is approved in Europe for the metabolic disease Familial Lipoprotein Lipase Deficiency. It is currently being tested in clinical trials in the U.S. to treat other rare conditions like the retinal Leber Congenital Amaurosis and the...
• Mechanically-Activated Drug Targeting Nanotechnology
  The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...
• Human Organs-on-Chips
  Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to...
• Microfluidic Hemostasis Monitor
  The body’s ability to stop bleeding, also known as hemostasis, is critical for survival. For patients with blood clotting disorders, medical conditions requiring the use of anticoagulation or antiplatelet drugs, or who require treatment with extracorporeal devices that circulate their blood outside of the body, it is essential that care providers can rapidly monitor their...

News 41

View all

• Press Release Wyss Institute’s Organ Chips get smart and go electric
  June 14, 2017
• Video/​Animation Gene Therapy: The Age of AAV
  May 23, 2017
• Press Release Pulmonary Thrombosis-on-a-Chip provides new avenue for drug development
  May 22, 2017

Multimedia 2

• 

  Video/Animation
  Smoking Human Lung Small Airway-on-a-Chip
  In this video, Wyss Founding Director Donald Ingber and Technology Development Fellow Kambez Benam explain how the integrated smoking device mimics normal cigarette smoke exposure and how it can impact research into the causes of COPD and into new biomarkers and therapeutics. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  Small Airway-on-a-Chip: Modeling COPD and Asthma
  Development of new therapeutics for chronic lung diseases have been hindered by the inability to study them in vitro. To address this challenge, Wyss Institute researchers used their Organ-on-a-Chip technology to produce a microfluidic ‘human lung small airway-on-a-chip.’ The device, which is composed a clear rubber material, is lined by living Human lung small airway...